Study guide

6.2 Acute Ischemic Stroke, Hemorrhagic Stroke & Subarachnoid Hemorrhage

IBSC CCP-C Certified Critical Care Paramedic Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Exam Strategy

1.1 About the CCP-C Exam 1.2 CCP-C Study Strategy & Exam Tactics

2 Chapter 2: Transport and Safety (Part 1)

2.1 Crew Resource Management & Sterile Cockpit Rule 2.2 Transport Risk Assessment & Mission Decision-Making 2.3 Aircraft and Ground Transport Safety Protocols

3 Chapter 2: Transport and Safety (Part 2)

2.4 Environmental Transport Stressors & Gas Laws 2.5 Transport Equipment Management & Post-Mission Operations

4 Chapter 3: Airway, Anesthesia, and Analgesics (Part 1)

3.1 Advanced Airway Assessment & Difficult Airway Identification 3.2 Rapid Sequence Induction (RSI) - Pretreatment & Induction Agents 3.3 Neuromuscular Blockade - Depolarizing vs Non-Depolarizing Agents 3.4 Post-Intubation Sedation, Analgesia & Dissociative Maintenance 3.5 Transport Ventilator Setup & Primary Ventilation Modes

5 Chapter 3: Airway, Anesthesia, and Analgesics (Part 2)

3.6 Mechanical Ventilator Waveforms, Loops & Oxygenation Titration 3.7 Ventilator Alarm Troubleshooting & Peak vs Plateau Pressures 3.8 Rescue Airway Devices, Video Laryngoscopy & Surgical Cricothyrotomy 3.9 Neuromuscular Reversal & Vasoactive Airway Support 3.10 Transport Airway Management in Unique Environments & Extubation

6 Chapter 4: General Medical Patient

4.1 Sepsis, Severe Sepsis & Septic Shock Resuscitation 4.2 Endocrine Emergencies (DKA, HHS, Adrenal Crisis, Thyroid Storm) 4.3 Renal and Hepatic Emergencies in Transport

7 Chapter 5: Cardiac Patient

5.1 Acute Coronary Syndromes & Infarct Specific Complications 5.2 Invasive Hemodynamic Monitoring 5.3 Vasoactive & Inotropic Medication Titration 5.4 Mechanical Circulatory Support & Post-Cardiac Arrest Care

8 Chapter 6: Neurological Patient

6.1 Traumatic Brain Injury & Intracranial Pressure (ICP) Management 6.2 Acute Ischemic Stroke, Hemorrhagic Stroke & Subarachnoid Hemorrhage 6.3 Status Epilepticus, Spinal Cord Injury & Neurogenic Shock

9 Chapter 7: Respiratory Patient

7.1 Acute Respiratory Distress Syndrome (ARDS) & Lung-Protective Ventilation 7.2 Severe Asthma & COPD Exacerbations in Critical Care 7.3 Chest Tube Management, Pleural Drains & Tension Pneumothorax 7.4 Pulmonary Embolism, Pulmonary Hypertension & Transport Respiratory Meds

10 Chapter 8: Toxic Exposure and Environmental Patient

8.1 Toxicology Emergencies, Toxidromes & Antidote Therapy 8.2 Environmental Emergencies (Hypothermia, Hyperthermia, Frostbite) 8.3 Submersion, Diving Emergencies & Envenomation/HazMat

11 Chapter 9: Trauma and Burn Patient

9.1 Hemorrhagic Shock Resuscitation & Massive Transfusion Protocols (MTP) 9.2 Severe Thoracic & Abdominal Trauma Management 9.3 Thermal, Chemical & Electrical Burn Assessment & Fluid Resuscitation 9.4 Musculoskeletal Trauma, Pelvic Fractures & Compartment Syndrome

12 Chapter 10: Maternal and Fetal Medicine

10.1 High-Risk Obstetric Assessment & Hypertensive Disorders of Pregnancy 10.2 Obstetric Hemorrhage, Placental Abruption & Preterm Labor 10.3 Emergency Transport Delivery, Umbilical Cord Prolapse & Fetal Monitoring

13 Chapter 11: Pediatric Patient

11.1 Pediatric Critical Care Airway & Transport Ventilation 11.2 Pediatric Shock, Dehydration & Weight-Based Dosing 11.3 Neonatal Resuscitation Program (NRP) & Transport of the Critical Neonate

14 Chapter 12: Special Populations

12.1 Bariatric Critical Care Transport & Positional Management 12.2 Geriatric Critical Care & Patients with Specialized Medical Technology

15 Chapter 13: Professional Considerations

13.1 Legal Aspects, EMTALA & Transport Ethics 13.2 Quality Improvement, Transport Safety Research & Evidence-Based Practice

6.2 Acute Ischemic Stroke, Hemorrhagic Stroke & Subarachnoid Hemorrhage

Key Takeaways Explain This Topic AI

Intravenous thrombolysis with alteplase (0.9 mg/kg) or tenecteplase (0.25 mg/kg) is indicated within 4.5 hours of last known normal (LKN) in acute ischemic stroke.

Blood pressure thresholds depend on thrombolytic eligibility: < 185 / 110 mmHg < 185/110 \text{ mmHg} < 185/110 mmHg prior to thrombolysis ( < 180 / 105 mmHg < 180/105 \text{ mmHg} < 180/105 mmHg post-tPA) versus < 220 / 120 mmHg < 220/120 \text{ mmHg} < 220/120 mmHg in non-candidates.

IV antihypertensives are titrated to the stroke-specific BP target. Clevidipine starts at 1 – 2 mg/hr 1\text{--}2\text{ mg/hr} 1 – 2 mg/hr ; its 24-hour lipid-load limit is an average 21 mg/hr 21\text{ mg/hr} 21 mg/hr , distinct from the limited experience with short-term rates up to 32 mg/hr 32\text{ mg/hr} 32 mg/hr .

For acute spontaneous ICH presenting with SBP 150 – 220 mmHg 150\text{--}220\text{ mmHg} 150 – 220 mmHg , 2025 AHA/ACC guidance supports lowering to 130 to < 140 mmHg 130\text{ to }<140\text{ mmHg} 130 to < 140 mmHg for at least 7 days; hold antihypertensives if SBP falls below 130 mmHg 130\text{ mmHg} 130 mmHg . Individualize for severity and local stroke protocol; urgently reverse relevant anticoagulation.

Subarachnoid hemorrhage (SAH) management utilizes Hunt-Hess and Fisher grading, enteral Nimodipine ( 60 mg 60 \text{ mg} 60 mg q4h) for vasospasm prevention, and euvolemic hypertension.

Last updated: September 2026

6.2 Acute Ischemic Stroke, Hemorrhagic Stroke & Subarachnoid Hemorrhage

Cerebrovascular emergencies rank among the most time-sensitive conditions encountered in critical care transport. Rapid neurological assessment, precise blood pressure titration, timely administration of thrombolytic agents, urgent reversal of anticoagulation, and prevention of secondary vasospasm are vital to preserving viable brain tissue and preventing permanent disability.

Acute Ischemic Stroke (AIS) & Reperfusion Therapy

Acute Ischemic Stroke accounts for approximately 87% of all strokes. Ischemic tissue surrounding the dense infarcted core is known as the ischemic penumbra —a region of hypoperfused but metabolically active, potentially salvageable brain tissue.

Thrombolytic Time Windows & Dosing

Intravenous Recombinant Tissue Plasminogen Activator (rtPA / Alteplase) :

Treatment Window : Within 4.5 hours of "Last Known Normal" (LKN).

Dosing : 0.9 mg/kg 0.9 \text{ mg/kg} 0.9 mg/kg IV (maximum total dose 90 mg 90 \text{ mg} 90 mg ). Administer 10 % 10\% 10% of total dose as an initial IV bolus over 1 minute, followed by the remaining 90 % 90\% 90% as a continuous infusion over 60 minutes.

Tenecteplase (TNK-tPA) :

Treatment Window : Within 4.5 hours of LKN (increasingly preferred due to single IV bolus administration).

Dosing : 0.25 mg/kg 0.25 \text{ mg/kg} 0.25 mg/kg IV single bolus (maximum total dose 25 mg 25 \text{ mg} 25 mg ).

Endovascular Thrombectomy (EVT) : Indicated up to 24 hours from LKN for patients with Large Vessel Occlusions (LVO) in the anterior circulation, determined by CT angiogram and perfusion mismatch.

Blood Pressure Management Thresholds in AIS

Blood pressure management in acute ischemic stroke is tightly regulated based on whether the patient is eligible to receive intravenous thrombolysis.

Clinical Scenario Initial BP Threshold to Start Treatment Post-Treatment Maintenance BP Target

tPA / TNK Candidate MUST lower BP to < 185 / 110 mmHg < 185/110 \text{ mmHg} < 185/110 mmHg prior to initiating thrombolytic infusion. Maintain BP < 180 / 105 mmHg < 180/105 \text{ mmHg} < 180/105 mmHg for at least 24 hours post-thrombolysis to prevent intracerebral hemorrhage.

Non-tPA Candidate Allow Permissive Hypertension . Treat ONLY if SBP > 220 mmHg > 220 \text{ mmHg} > 220 mmHg or DBP > 120 mmHg > 120 \text{ mmHg} > 120 mmHg . Reduce MAP by 15 % 15\% 15% over the first 24 hours . Avoid abrupt BP drops to maintain penumbral perfusion.

Rationale for Permissive Hypertension : In non-thrombolytic candidates, elevated blood pressure is a compensatory reflex maintaining collateral arterial perfusion through cerebral vessel networks into the ischemic penumbra. Precipitous lowering of BP collapses collateral flow, enlarging the stroke infarct size.

First-Line Anti-Hypertensive Infusions

Use titratable IV agents when urgent BP control is indicated; the agent, bolus or infusion strategy, and target depend on the stroke scenario and local protocol. Clevidipine dosing below follows the Cleviprex prescribing information, section 2.2 .

Antihypertensive Agent Class & Mechanism Standard Dosing & Titration Clinical Pearls & Contraindications

Nicardipine (Cardene) Dihydropyridine Calcium Channel Blocker (causes arterial vasodilation) Start 5 mg/hr 5 \text{ mg/hr} 5 mg/hr IV; titrate by 2.5 mg/hr 2.5 \text{ mg/hr} 2.5 mg/hr every 5–15 min to max 15 mg/hr 15 \text{ mg/hr} 15 mg/hr . Excellent cerebral selectivity. Does not increase ICP. Requires large peripheral or central line (venous irritant).

Clevidipine (Cleviprex) Ultra-short-acting Dihydropyridine CCB (metabolized by blood esterases) Start 1 – 2 mg/hr 1\text{--}2\text{ mg/hr} 1 – 2 mg/hr IV. Initially may double at 90-second intervals; near target, use smaller increases every 5–10 min. Most respond at 4 – 6 mg/hr 4\text{--}6\text{ mg/hr} 4 – 6 mg/hr . Limited short-term experience exists up to 32 mg/hr 32\text{ mg/hr} 32 mg/hr ; do not exceed 1,000 mL or an average 21 mg/hr 21\text{ mg/hr} 21 mg/hr over 24 hours because of lipid load. Ultra-rapid onset ( 2 − 4 min 2-4 \text{ min} 2 − 4 min ) and offset. Contraindicated in soy/egg allergy, defective lipid metabolism, or severe aortic stenosis. Monitor BP and heart rate continuously.

Labetalol (Trandate) Combined α 1 \alpha_1 α 1 ​ and non-selective β \beta β -blocker ( 1 : 7 α : β 1:7 \ \alpha:\beta 1 : 7 α : β ratio IV) 10 − 20 mg 10-20 \text{ mg} 10 − 20 mg IV push over 1–2 min; double dose q10min (max 300 mg 300 \text{ mg} 300 mg ), or infusion 2 − 8 mg/min 2-8 \text{ mg/min} 2 − 8 mg/min . Avoid in severe bradycardia ( H R < 60 HR < 60 H R < 60 ), 2nd/3rd degree heart block, decompensated heart failure, or severe asthma.

Acute Spontaneous Intracerebral Hemorrhage (ICH)

Intracerebral hemorrhage involves primary bleeding into the brain parenchyma, most commonly caused by chronic hypertension, cerebral amyloid angiopathy, or vascular malformations. Hematoma expansion occurs rapidly within the first 3–6 hours.

Blood Pressure Reduction in ICH

2025 AHA/ACC guidance: For adults with acute spontaneous ICH and initial SBP 150 – 220 mmHg 150\text{--}220\text{ mmHg} 150 – 220 mmHg , lowering SBP to 130 to < 140 mmHg 130\text{ to }<140\text{ mmHg} 130 to < 140 mmHg for at least 7 days can improve outcomes; stop antihypertensive medication if SBP falls below 130 mmHg 130\text{ mmHg} 130 mmHg . 2025 guideline, section 5.3.9.1 .

Titrate smoothly under the local stroke protocol. Large/severe hemorrhage, impaired cerebral perfusion, or planned decompression requires an individualized plan with the stroke/neurosurgical team.

Urgent Anticoagulant Reversal Protocols

For patients presenting with acute ICH while on anticoagulant therapy, immediate reversal is paramount prior to or during transport.

Anticoagulant Agent Reversal Antidote / Agent Specific Dosing & Administration Protocol

Warfarin (Coumadin) 4-Factor Prothrombin Complex Concentrate (4F-PCC / Kcentra) + Vitamin K 4F-PCC 25 − 50 units/kg 25 - 50 \text{ units/kg} 25 − 50 units/kg IV based on baseline INR and body weight + Vitamin K 10 mg 10 \text{ mg} 10 mg slow IV infusion in 50 − 100 mL 50-100 \text{ mL} 50 − 100 mL NS over 30 min.

Dabigatran (Pradaxa) Idarucizumab (Praxbind) 5 g 5 \text{ g} 5 g IV total, administered as two consecutive 2.5 g 2.5 \text{ g} 2.5 g bolus doses (humanized monoclonal antibody fragment).

Factor Xa Inhibitors (Rivaroxaban, Apixaban) Andexanet Alfa (Andexxa) or 4F-PCC (Kcentra) Andexxa IV bolus followed by a 2-hour continuous infusion (recombinant modified human Factor Xa). Alternatively, high-dose 4F-PCC ( 50 units/kg 50 \text{ units/kg} 50 units/kg IV).

Unfractionated Heparin (UFH) Protamine Sulfate 1 mg 1 \text{ mg} 1 mg Protamine per 100 units 100 \text{ units} 100 units UFH given in the past 2–3 hours (max single dose 50 mg 50 \text{ mg} 50 mg slow IV over 10 min).

LMWH (Enoxaparin) Protamine Sulfate 1 mg 1 \text{ mg} 1 mg Protamine per 1 mg 1 \text{ mg} 1 mg Enoxaparin administered within the preceding 8 hours.

Subarachnoid Hemorrhage (SAH) & Vasospasm Management

Aneurysmal Subarachnoid Hemorrhage (aSAH) results from the rupture of an intracranial saccular ("berry") aneurysm into the subarachnoid space. Patients present with classic "thunderclap headache" ("worst headache of life"), vomiting, nuchal rigidity, photophobia, and rapid loss of consciousness.

SAH Clinical & Radiographic Grading

Grading System Parameter Assessed Clinical & Radiographic Criteria

Hunt-Hess Scale Clinical Severity & Surgical Mortality Grade 1 : Asymptomatic or mild headache.; Grade 2 : Moderate-to-severe headache, nuchal rigidity, no neural deficit.; Grade 3 : Drowsy, confused, mild focal deficit.; Grade 4 : Stuporous, moderate-to-severe hemiparesis.; Grade 5 : Deep coma, decerebrate posturing.

Fisher Grade Non-contrast CT Blood Burden & Vasospasm Risk Grade 1 : No subarachnoid blood detected.; Grade 2 : Diffuse thin layer of blood ( < 1 mm < 1 \text{ mm} < 1 mm thick).; Grade 3 : Localized clot and/or thick layer of blood ( > 1 mm > 1 \text{ mm} > 1 mm thick) — High Risk of Vasospasm .; Grade 4 : Intracerebral or intraventricular blood with diffuse or no SAH.

Delayed Cerebral Ischemia (DCI) & Vasospasm Prevention

Cerebral vasospasm typically develops between days 4 and 14 post-hemorrhage as blood breakdown products irritate cerebral arteries.

Enteral Nimodipine : Oral/nasogastric calcium channel blocker administered as 60 mg 60 \text{ mg} 60 mg PO/NG every 4 hours for 21 consecutive days . Nimodipine improves neurological outcomes through neuroprotective actions. Warning: Nimodipine must NEVER be administered intravenously; IV administration causes severe refractory vasodilation and fatal cardiac arrest.

Euvolemic Hypertension vs. Historical Triple-H Therapy : Historical "Triple-H Therapy" (Hypervolemia, Arterial Hypertension, Hemodilution) has been abandoned due to high risks of pulmonary edema, myocardial infarction, and hyponatremia. Current critical care standard dictates maintaining strict EUVOLEMIA using isotonic crystalloids ( 0.9 % 0.9\% 0.9% NaCl) and initiating induced arterial hypertension (using norepinephrine infusion to target MAP 90 − 110 mmHg 90 - 110 \text{ mmHg} 90 − 110 mmHg ) ONLY if symptomatic cerebral vasospasm occurs.